Mitochondria as biosynthetic factories for cancer proliferation.

Ahn CS, Metallo CM. · 2015

Read Mitochondria as biosynthetic factories for cancer proliferation. by Ahn CS, Metallo CM. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4305394.txt.

Introduction

Christopher S Ahn and Christian M Metallo argue that mitochondria, far from being shut down in cancer, act as factories that feed tumor growth. Their review appeared in Cancer and Metabolism in 2015. Many cancer cells favor fast sugar breakdown, which led to an old assumption that their mitochondria were broken or idle.

In fact tumors keep working mitochondria and often push more material through them. The organelles supply the building blocks for fats, amino acids, and nucleotides that dividing cells need in bulk. Blocking these supply lines slows some tumors in tests, which makes mitochondrial metabolism a live drug target. The review gathers the evidence pathway by pathway.

Catalog record

CREATORAhn CS, Metallo CM.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4305394

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Mitochondria as biosynthetic factories for cancer proliferation By Christopher S Ahn, Christian M Metallo Published in: Cancer & Metabolism DOI: 10.1186/s40170-015-0128-2 ABSTRACT Unchecked growth and proliferation is a hallmark of cancer, and numerous oncogenic mutations reprogram cellular metabolism to fuel these processes. As a central metabolic organelle, mitochondria execute critical biochemical functions for the synthesis of fundamental cellular components, including fatty acids, amino acids, and nucleotides. Despite the extensive interest in the glycolytic phenotype of many cancer cells, tumors contain fully functional mitochondria that support proliferation and survival. Furthermore, tumor cells commonly increase flux through one or more mitochondrial pathways, and pharmacological inhibition of mitochondrial metabolism is emerging as a potential therapeutic strategy in some cancers. Here, we review the biosynthetic roles of mitochondrial metabolism in tumors and highlight specific cancers where these processes are activated. REVIEW Recent characterizations of metabolic enzymes as tumor suppressors and oncogene-driven metabolic reprogramming have reinvigorated interest in cancer metabolism. Although therapies targeting metabolic processes have long been a staple in cancer treatment (e.g. inhibition of folate metabolism via methotrexate), the focused therapeutic potential surrounding these findings have generated a renewed appreciation for Otto Warburg’s work almost a century ago. Warburg observed that tumor cells ferment much of the glucose taken up during growth to lactate, thus using glycolysis as a major means of adenosine triphosphate (ATP) regeneration [1]. However, the observation of decreased respiration in cancer cells and idea that “the respiration of all cancer cells is damaged” belies the critical role of mitochondria in biosynthesis and cell survival [1]. On the contrary, functional mitochondria are present in all proliferative cells within our body (including all tumors), as they are responsible for converting the diverse nutrients available to cells into the fundamental building blocks required for cell growth. These organelles execute numerous functions in cancer cells to promote tumor growth and survival in response to stress. Here, we outline the critical biosynthetic functions served by mitochondria within tumors (Figure 1). Although many of these functions are similarly important in normal, proliferating cells, we have attempted to highlight potential points where mitochondrial metabolism may be therapeutically targeted to slow cancer growth. This review is organized by specific metabolic pathways or processes (i.e., glucose metabolism and lipogenesis, amino acid metabolism, and nucleotide biosynthesis). Tumors or cancer cell types where enzymes in each pathway have been specifically observed to by dysregulated are described within the text and summarized in Table 1.Figure 1 Biosynthetic nodes within mitochondria. Metabolic pathways within mitochondria that contribute to biosynthesis in cancer and other proliferating cells. TCA metabolism and FOCM enable cells to convert carbohydrates and amino acids to lipids, non-essential amino acids, nucleotides (including purines used for cofactor synthesis), glutathione, heme, and other cellular components. Critical biosynthetic routes are indicated by yellow arrows. Enzymatic reactions that are dependent on redox-sensitive cofactors are depicted in red.Table 1 Overview of mitochondrial biosynthetic enzymes important in cancer Cancer type (according to primary site) Blood, bone, or lymph Brain Breast Colon Kidney Liver Lung Stomach Ovarian Pancreas Prostate Skin TCA cycle, anaplerosis, and AcCoA metabolism Pyruvate carboxylase • • • • • • • • Pyruvate dehydrogenase complex • • • • • • • • Isocitrate dehydrogenase (activity or mutation) • • • • • • • • • Succinate dehydrogenase (mutation) • Fumarate hydratase (mutation) • Glutaminase and/or glutamate dehydrogenase • • • • • • • • • Glutamine synthetase • • • Amino acid metabolism Pyrroline-5-carboxylate reductase • • • • • • • • • • Proline oxidase • • • • • • • • • • • • Aspartate transaminase • • • Alanine transaminase • • • • • • Nucleotide biosynthesis Dihydroorotate dehydrogenase • • • • • • • • Methylenetetrahydrofolate dehydrogenase • • • • • • • • • • • Cancers in which three or more mitochondrial enzymes have been studied and found to be differentially regulated (or mutated, as indicated) in cancers vs. control groups are included. Dysregulation of each enzyme was demonstrated in clinical tumors samples, animal models, or cell lines at the levels of genes, mRNA, protein, metabolites, and/or flux. Glucose anaplerosis Glucose is the most widely available nutrient in our body; not surprisingly, most tumor cells consume this carbohydrate (or analogs) at high rates. This phenotype allows for detection and imaging of some cancers and metastatic lesions using the glucose analog 2-deoxy-2-[18 F]fluoro-D-glucose (FDG), which accumulates in tumors (and some other tissues) and can be noninvasively observed when using positron emission tomography integrated with computed tomography (FDG-PET/CT) [2]. While FDG-PET/CET tracks cells with high glucose uptake and phosphorylation only, the use of isotope tracers, mass spectrometry (MS), and nuclear magnetic resonance (NMR) have enabled researchers to more closely examine the fate of glucose within cancer cells [3-5]. Indeed, flux through glycolysis and lactate secretion remains a hallmark of many tumor cells, presumably to facilitate biosynthesis of ribose, purines (via serine and glycine), and lipid headgroups (via glycerol-3-phosphate and serine). However, increasing evidence now indicates that cancer cells transport a significant portion of glucose-derived pyruvate into mitochondria where it serves as an anaplerotic substrate to replenish tricarboxylic acid (TCA) cycle intermediates used for biosynthesis. For example, conditions of limited glutamine availability or glutaminase (GS) suppression drive cancer cells to increasingly rely on glucose carbon flux through pyruvate carboxylase (PC) to maintain oxaloacetate (OAC) production and downstream TCA cycle activity [6]. Furthermore, NMR analysis of mice bearing three distinct human orthotopic tumors and infused with [3,4-13C2]glucose indicated these glioblastoma lines used glucose as a mitochondrial anaplerotic substrate [7]. Although glutamine is one of the most abundant amino acids present in plasma, typical in vitro culture media used for cell line expansion contain relatively high concentrations (2–4 mM) of glutamine. Thus, as tumor cells are increasingly analyzed prior to “adaptation/selection” in vitro, we are beginning to better appreciate the importance of glucose-derived pyruvate as an anaplerotic substrate in tumors. Glucose oxidation and lipogenesis Beyond flux through PC or analogous reactions, the more predominant fate of mitochondrial pyruvate is oxidation by the pyruvate dehydrogenase (PDH) complex to form acetyl-coenzyme A (AcCoA). AcCoA is subsequently converted to citrate via condensation with OAC by citrate synthase. In turn, citrate is either converted to isocitrate in the TCA cycle or transported out of mitochondria and metabolized by ATP citrate lyase to yield cytosolic AcCoA, which is the substrate for de novo lipogenesis and acetylation. Mitochondrial activity within this pyruvate-citrate shuttle is therefore critical for the biosynthesis of fatty acids and cholesterol as well as protein acetylation. With some notable exceptions (e.g. hypoxia, discussed below), most cancer cells derive the majority of their lipogenic AcCoA from glucose-derived pyruvate through PDH [8-10]. Numerous oncogenic pathways stimulate glucose-derived carbon atom flux through the citrate shuttle to promote lipogenesis and TCA metabolism. Specific mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) stimulate flux of glucose through PDH to generate fatty acids [11,12]. Alternatively, active Akt promotes glucose-mediated fatty acid synthesis downstream of PDH [8,13]. This Akt-dependent lipogenesis occurs by activation of mammalian target of rapamycin complex 1 (mTORC1) and sterol regulatory element-binding protein 1 (SREBP1), which are key regulators of cellular growth and lipid homeostasis, respectively [14]. Interestingly, SREBPs

Read the complete text